Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.88 −0.7% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.74 +3.0% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.88 −0.7% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.74 +3.0% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
M&A / Property Routine +

Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

By The Northwire Desk — AI Analysis Apr 15, 2026 · 07:05 ACB · 4.89 AURORA CANNABIS INC. J
Executive Summary
  • Aurora Cannabis announced the acquisition of 100% of Safari Flower Company for an aggregate consideration valued at $26.5 million.
  • The transaction includes a 59,000 square foot purpose-built indoor cultivation and manufacturing facility in Ontario, Canada, certified for EU GMP standards.
  • Payment structure involves issuance of 2,417,180 common shares, $15 million cash payment, and up to $2 million contingent cash payment.
  • Strategic objective is to increase supply of high-quality, EU GMP manufactured flower for international markets including Germany, Australia, Poland, and the UK.
  • Financial projections indicate expected positive Adjusted EBITDA contributions starting in fiscal year 2027.
Material Impact
  • The acquisition aligns with the company's stated "Global Medical Growth Strategy" and follows the February 2026 ATM offering authorization for M&A activity, making it an expected execution of prior plans rather than a surprise catalyst.
  • While strategically sound for expanding high-margin EU capacity, the immediate financial impact is neutral-to-negative due to cash outflow ($15M) and equity dilution (2.4M shares), with profitability benefits deferred until FY27.
  • Given the stock's significant decline from its September 2025 peak ($8.66) to current levels ($4.89), previous positive announcements regarding product launches and IP rights failed to sustain price momentum, suggesting market skepticism regarding capital allocation efficiency.
  • The deal is accretive in the long term but does not resolve immediate liquidity concerns or near-term profitability gaps highlighted in Q2 FY26 results where free cash flow remained negative at $(42.3)M.
ACB · Price
Company Overview
  • Aurora Cannabis operates as a global medical cannabis company with a focus on high-margin international markets.
  • Flagship projects include EU GMP certified cultivation facilities in Ontario (Safari Flower acquisition) and existing operations in Canada, Australia, Poland, Germany, and the UK.
  • The company emphasizes proprietary genetics and R&D, evidenced by recent Community Plant Variety Rights grants for Farm Gas and Sourdough varieties.
Read the original news release →

More from AURORA CANNABIS INC. J

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Feb 11, 2026 · 15:41

Aurora Cannabis expands portfolio in Australia, N.Z.

Other